Revance Therapeutics | L'Utile Operativo



Operating Profit Cambiamento Data
AbbVie USD 3.73B 5.22B 2025-03
ALKERMES USD 13.79M 148.9M 2025-03
Bristol-Myers Squibb USD 3.41B 2.62B 2025-03
Eli Lilly USD 5.41B 259.6M 2025-03
J&J USD 13.63B 9.74B 2025-03
Merck USD 5.87B 1.57B 2025-03
Neurocrine Biosciences USD 142M 41.8M 2024-12
P&G USD 4.55B 1.21B 2025-03
Pacira USD 1.99M 22.71M 2025-03
Supernus Pharmaceuticals USD 21.4M 19.44M 2024-12



Revance Therapeutics L'Utile Operativo - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Jul 2025.